Viral Vector Manufacturing Market to Surpass USD 5 Billion by 2030
Viral Vectors are Essential Components in gene therapy, cell-based treatments, and vaccine development. They act as carriers to deliver genetic material into cells. As the demand for targeted therapies increases, so does the need for high-quality, scalable viral vector production. The market’s growth is fueled by advancements in bioprocessing, a surge in gene therapy clinical trials, and rising funding from both public and private sectors. To Get Sample Report: https://www.datamintelligence.com/download-sample/viral-vector-manufacturing-market Market Drivers and Growth Opportunities 1. Gene Therapy Pipeline Expansion Gene therapy is one of the primary catalysts for market growth. Hundreds of clinical trials are underway globally, particularly for cancer and rare diseases, significantly increasing demand for viral vectors. 2. Oncology Segment Growth Cancer therapies using viral vectors are surging. The oncology application alone is expected to grow from USD 1.33 billion in 2024 to ap...